Auraptene ameliorates osteoporosis by inhibiting RANKL/NFATc1 pathway-mediated bone resorption based on network pharmacology and experimental evaluation

Auraptene ameliorates osteoporosis by inhibiting RANKL/NFATc1 pathway-mediated bone resorption based on network pharmacology and experimental evaluation

Aims: The association of auraptene (AUR), a 7-geranyloxycoumarin, on osteoporosis and its potential pathway was predicted by network pharmacology and confirmed in experimental osteoporotic mice. Methods: The network of AUR was constructed and a potential pathway predicted by Kyoto Encyclopedia of Ge...

Full description

Bibliographic Details
Main Authors: Mi H. Kim, La Y. Choi, Jae Y. Chung, Eun-Jung Kim, Woong M. Yang
Format: Article
Language:English
Published: The British Editorial Society of Bone & Joint Surgery 2022-05-01
Series:Bone & Joint Research
Subjects:
auraptene
osteoporosis
bone mineral density
osteoclast
rankl/nfatc1
osteoporotic bone
bone resorption
osteoclasts
femora
bone mineral density (bmd)
serum
calcium
bone loss
tibia
rna
Online Access:https://online.boneandjoint.org.uk/doi/epdf/10.1302/2046-3758.115.BJR-2021-0380.R1

Internet

https://online.boneandjoint.org.uk/doi/epdf/10.1302/2046-3758.115.BJR-2021-0380.R1

Similar Items